PharmaShots | Incisive News in 3 Shots

Subscribe Now

Aspect NP study

Merck's ZERBAXA Achieves 1EP of Non-Inferiority in P-III ASPECT-NP study for the Treatment of HABP or VABP in adults

Merck's ZERBAXA Achieves 1EP of Non-Inferiority in P-III ASPECT-NP study for the Treatment of HABP or VABP in adults

September 11, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us